ALEX E. BROWN, M.D., F.A.C.P.; WALLACE E. HERRELL, M.D.; J. ARNOLD BARGEN, M.D., F.A.C.P.
With the advent of the various sulfamido compounds into the field of medical therapeutics it seemed reasonable, as we have stated in a previous article to investigate the effect of these preparations on patients who have chronic ulcerative colitis.
In using the term "chronic ulcerative colitis," we are referring only to the thrombo-ulcerative form of the disease in which destructive and hyperplastic changes occur in the bowel. We felt that such a trial of therapy was justified because it seemed likely that the organism responsible for the disease might be susceptible to the effect of these sulfamido compounds. In a
Learn more about subscription options.
Register Now for a free account.
BROWN AE, HERRELL WE, BARGEN JA. NEOPRONTOSIL (ORAL) IN THE TREATMENT OF CHRONIC ULCERATIVE COLITIS(NEOPRONTOSIL (ORAL) IN THE TREATMENT OF CHRONIC ULCERATIVE COLITIS*). Ann Intern Med. 1939;13:700–714. doi: 10.7326/0003-4819-13-4-700
Download citation file:
Published: Ann Intern Med. 1939;13(4):700-714.
Gastroenterology/Hepatology, Inflammatory Bowel Disease.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only